Even though CDKN2A heterozygous deletions are sufficient to confer a 67% risk of melanoma development, it was found that the mechanisms responsible for oncogenesis and tumor progression required clarification at the present time [48,49]. The gene discussed is CDKN2A; the disease is melanoma.